New prostate cancer drug combo tested in real patients across germany
NCT ID NCT07395804
Summary
This study will observe 500 men in Germany with advanced prostate cancer that has spread but still responds to hormone therapy. Doctors will track how well the combination of darolutamide (a newer hormone-blocking drug) plus standard hormone therapy works in everyday medical practice over 5 years. The main goal is to see how many men achieve very low prostate cancer marker levels after one year of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Locations
Multiple, Germany
Conditions
Explore the condition pages connected to this study.